If you've been tracking FDA Form 483 trends lately, you've probably noticed the headlines: "FDA Increases Inspections," "Common 483 Findings for 2026," and "Top Compliance Deficiencies to Avoid." These reports offer a surface-level view of what's happening in the regulatory landscape: a valuable starting point, but hardly the full story. At CompliantQS, we believe in […]
Regulatory setbacks happen. FDA warning letters, failed inspections, and 483 observations can feel like the end of the road for pharmaceutical companies. But they don't have to be. At Compliant Quality Systems Group LLC, we've seen firsthand how the right consulting partnership can transform compliance crises into competitive advantages. The key lies in systematic root […]
Welcome to Your New Monthly Dose of Compliance Intelligence Hey there, Pharma Professionals! I'm thrilled to kick off what I hope becomes your go-to monthly resource for staying ahead in the ever-evolving world of pharmaceutical compliance. This is the inaugural edition of our monthly newsletter, and frankly, I couldn't be more excited to share what […]
